Does yellow fever 17D vaccine protect against melanoma?

Vaccine

Volumn 27, Issue 4, 2009, Pages 588-591

  Mastrangelo, G ^a   Krone, B ^b   Fadda, E ^a   Buja, A ^a   Grange, J M ^c   Rausa, G ^a   de Vries, E ^d   Koelmel, K F ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer prevention; Cohort study; Melanoma; Nested case control study; Yellow fever vaccine

Indexed keywords

HERV K MEL ANTIGEN; MELANOMA ANTIGEN; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; ENDOGENOUS RETROVIRUS; FEMALE; HUMAN; HUMAN ENDOGENOUS RETROVIRUS K; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; VACCINATION; YELLOW FEVER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MELANOMA; MIDDLE AGED; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 57749205951     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.076     Document Type: Article

References (15)

1. Markovic S.N., Erickson L.A., Rao R.D., Weenig R.H., Pockaj B.A., Bardia A., et al. Malignant melanoma in the 21st century. Part 1. Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 82 (2007) 364-380
2. Krone B., Kölmel K.F., Grange J.M., Mastrangelo G., Henz B.M., Botev I.N., et al. Impact of vaccinations and infectious diseases on melanoma risk-evaluation of an EORTC case-control-study. Eur J Cancer 39 (2003) 2372-2378
3. Kölmel K.F., Pfahlberg A., Mastrangelo G., Niin M., Botev I.N., Seebacher C., et al. Infections and melanoma risk: results of a multicentric EORTC case-control-study. Melanoma Res 9 (1999) 511-519
4. Pfahlberg A., Kölmel K.F., Grange J.M., Mastrangelo G., Krone B., Botev I.N., et al. Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study. J Invest Dermatol 119 (2002) 570-575
5. Kölmel K.F., Grange J.M., Krone B., Mastrangelo G., Rossi C.R., Henz B.M., et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with a better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 41 (2005) 118-125
6. Schiavetti F., Thonnard J., Colau D., Boon T., and Coulie P.G. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 62 (2002) 5510-5516
7. Krone B., Koelmel K.F., Henz B.M., and Grange J.M. Protection against melanoma by vaccination with Bacille Calmette-Guérin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 41 (2005) 104-117
8. Merante F., Altamentova S.M., Mickle D.A., Weisel R.D., Thatcher B.J., Martin B.M., et al. The characterization and purification of a human transcription factor modulating the glutathione peroxidase gene in response to oxygen tension. Mol Cell Biochem 229 (2002) 73-83
9. Chakraborty D.P., and Roy A. Chemical and biological aspects of melanin. Alkaloids Chem Biol 60 (2003) 345-391
10. Kim R., Emi M., and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121 (2007) 1-14
11. Saenz AC. Yellow fever vaccines: achievements, problems, needs. In: Proceedings of the International Conference on the Application of Vaccines against Viral, Rickettsial, and Bacterial Diseases of Man. Section A. Arbovirus Diseases (Sci Pub No 226). Washington, DC: Pan-American Health Organization; 1971. p. 31.
12. Brès P. Benefit versus risk factors in immunization against yellow fever. Dev Biol Stand 43 (1979) 297-304
13. Martin M., Weld L.H., Tsai T.F., Mootrey G.T., Chen R.T., Niu M., et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7 (2001) 945-951
14. Monath T.P. Yellow fever vaccine. In: Plotkin S.A., Orenstein W.A., and Offitt P.A. (Eds). Vaccines. 4th ed. (2004), Saunders, Philadelphia 1095-1176
15. Henderson D.A., Borio L.L., and Lane J.M. Smallpox and vaccinia. In: Plotkin S.A., Orenstein W.A., and Offitt P.A. (Eds). Vaccines. 4th ed. (2004), Saunders, Philadelphia 123-153